Welcome to our dedicated page for Denali Therapeut SEC filings (Ticker: DNLI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC filings on neuro-focused biotech like Denali Therapeutics can feel like graduate-level reading. Pages of R&D cost break-outs, clinical-trial risk factors, and milestone-based collaborations hide the signals investors need. Stock Titan’s AI-powered summaries surface them—no more hunting through footnotes when Denali reports a new blood-brain-barrier breakthrough or adjusts revenue from partnered programs.
Open any document—whether the Denali Therapeutics annual report 10-K simplified, the Denali Therapeutics quarterly earnings report 10-Q filing, or a Denali Therapeutics 8-K material events explained—and our AI translates the science and the accounting. Want real-time Denali Therapeutics Form 4 insider transactions? Alerts appear seconds after submission, complete with context on option grants and signal strength. Interactive guidance answers queries such as “understanding Denali Therapeutics SEC documents with AI” or “Denali Therapeutics proxy statement executive compensation.”
The result: sharper decisions in less time. Track Denali Therapeutics insider trading Form 4 transactions, compare R&D spend quarter over quarter, or dive into Denali Therapeutics earnings report filing analysis without wading through jargon. Filter for Denali Therapeutics executive stock transactions Form 4, follow Denali Therapeutics Form 4 insider transactions real-time, or bookmark amendments. Every form—10-K, 10-Q, 8-K, S-3, DEF 14A—is streamed directly from EDGAR and distilled into key takeaways, so Denali Therapeutics SEC filings explained simply become part of your daily workflow.
Lindblad Expeditions Holdings, Inc. (NASDAQ: LIND) filed an 8-K on 8 July 2025 announcing two related agreements with Natural Habitat, Inc. (NatHab) founder Ben Bressler.
- Third Amendment to Stockholders’ Agreement: the company replaced the one-time 2026 put right with a perpetual, annually exercisable put right allowing Bressler to sell his remaining NatHab interest to Lindblad at any year-end while he remains a shareholder.
- Second Amended & Restated Employment Agreement: (i) establishes a performance-based Bonus Pool tied to NatHab consolidated net profits, (ii) grants Bressler option rights that may be issued when the perpetual put is exercised, (iii) extends his employment term through 31 Dec 2028, and (iv) removes expired compensation references.
These changes secure the continued leadership of NatHab’s founder, align incentives with NatHab profitability, and give Lindblad flexible timing to acquire the remaining minority stake. However, the perpetual put and potential option issuance introduce an open-ended future cash or share outflow, which could affect capital allocation and dilution.
Denali Therapeutics Inc. (DNLI) filed a Form 144 indicating a planned insider sale of 495,282 common shares. The shares have an aggregate market value of approximately $7.10 million based on the broker’s data supplied in the filing. The proposed transaction will be executed through Jefferies LLC on or after 9 July 2025 on the NASDAQ exchange.
The shares were originally acquired on 21 August 2015 via a stock-option exercise. No sales by the same account holder were reported in the prior three-month period, and no non-cash consideration or special payment terms were disclosed. With 145 million shares outstanding, the planned sale represents roughly 0.34 % of total shares, suggesting limited dilution or float impact. No remarks, Rule 10b5-1 plan dates, or material adverse information were provided, and the filer attested to compliance with Rule 144 requirements.
Denali Therapeutics Inc. (Nasdaq: DNLI) filed a Form 8-K to disclose a material regulatory milestone. On July 7, 2025, the company announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to Denali’s Biologics License Application (BLA) for tividenofusp alfa, its investigational therapy for Hunter syndrome (MPS II). The news was released via a press release attached as Exhibit 99.1. No financial figures, earnings data, or transactions were included in the filing. The Priority Review designation signals that the agency will evaluate the submission under an expedited pathway, underscoring the product’s potential importance for an underserved patient population. Other than routine exhibit listings and signature blocks, the 8-K contains no additional disclosures.
FAQ
What is the current stock price of Denali Therapeut (DNLI)?
What is the market cap of Denali Therapeut (DNLI)?
What is Denali Therapeutics' core mission?
How does Denali's Transport Vehicle (TV) platform work?
Which diseases are targeted by Denali's current programs?
What makes Denali’s approach unique in the biotech industry?
How does Denali ensure the efficacy of its therapies?
Does Denali collaborate with other companies?
What role do biomarkers play in Denali's clinical development?
How does Denali address challenges in CNS drug delivery?
